Insulet (Nasdaq:PODD) today announced a duo of updates related to its Omnipod 5 system that includes a significant integration development.
The company submitted an updated mobile application for regulatory clearance and aims to integrate Omnipod 5 with the Abbott FreeStyle Libre 2.
Acton, Massachusetts-based Insulet plans to discuss a range of developments related to its product line in the coming days at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego. Presentations include real-world evidence of improved outcomes and optimization using the Omnipod 5 automated insulin delivery system.
News of these developments follows the UK launch of Omnipod 5 earlier this week.
Get the full story at our sister site, Drug Delivery Business News.